Pronova BioPharma has entered into long term licence and supply
agreements and works closely with strong regional partners for the
distribution of Omacor and Lovaza in 46 countries.
The combined sales force focused in this network on the sale of Omacor/
Lovaza totalled more than 1 750 individuals during 2007. Some 600 of these
were sales professionals employed by Reliant Pharmaceuticals.
GlaxoSmithKline acquired Reliant in December 2007 and plans to more than
double the US sales force for Lovaza.
Together with our partners, we are also involved in phase III of clinical
trials for other cardiovascular diseases, such as atrial fibrillation.
Positive results from the GISSI heart failure phase III study were published
on 31 August 2008, demonstrating that Omacor/Lovaza Omacor® reduces
mortality and morbidity in patients with congestive heart failure (CHF).
Read more about our partners below:
Click on logo to navigate to partner's web sites
(Pronova BioPharma ASA is not responsible for external links)
|
Solvay Pharmaceuticals is part of the Solvay group of chemical
pharmaceutical companies, founded in 1863. Solvay Pharmaceuticals is active
in more than 40 countries with products available in more than 150 countries.
Solvay has an excellent position and reputation in Europe and growing presence
in the US and the Far East, and is one of Pronova BioPharma’s preferred partners
for alliances, licensing products, or for assistance in development, regulatory and
marketing matters.
Our license and supply agreement with Solvay covers the following markets:
United Kingdom, Ireland, Canada, Australia, Germany, Belgium, the Netherlands,
Eastern
Europe,
Middle East, Russia, Greece, South Africa, China, India and Southeast Asia.
|
|
Takeda is a research-based global pharmaceutical company. Takeda is the largest
pharmaceutical company in Japan, and one of the global leaders of the industry.Takeda's
in-house ethical drugs are marketed and a recognised brand in around 90 countries worldwide.
Ethical drugs are Takeda's core business, constituting over 80 per cent of total net sales.
Our license and supply agreement with Takeda covers the following markets:
Japan.
|
|
GlaxoSmithKline’s (GSK) is headquartered in the United Kingdom and with operations based
in the United States, GSK is one of the industry leaders. With a firm foundation in science,
GSK discovers, develops, manufactures and distributes vaccines, prescription medicines and
consumer health products.
Our license and supply agreement with GalxoSmithKline covers the following markets:
United States of America.
|
|
Laboratorios Ferrer, S.L. were founded in 1959. Ferrer products are being commercialised in
more than 60 countries. Commercialisation is carried out through subsidiaries, joint ventures,
licensees and distributors.
Our license and supply agreement with Ferrer covers the following markets:
Spain, Portugal, Germany, Greece,Central and South America and Southeast Asia.
|
| |
|
Kuhnil Pharmaceuticals was established in 1951 and is a fast-growing pharmaceutical company
well established in manufacturing, distributing, importing, and exporting pharmaceutical products in
South Korea. Kuhnil is now ranked within 5 per cent of almost 600 pharmaceutical companies in Korea.
Our license and supply agreement with Kuhnil Pharmaceuticals covers the following markets:
South Korea.
|
|
Laboratoires Pierre Fabre is a multinational pharmaceutical and cosmetics company based in
Castres, France, near Toulouse.Founded in 1961 by Pierre Fabre, it is present in over 130 countries
and has more than 9 000 employees (in 2003), 34 per cent of whom are internationally- based.
Our license and supply agreement with Laboratoires Pierre Fabre covers the following markets:
France.
|
|
Prospa BV. Our agreement with Prospa BV covers Italy. Prospa BV does not license the rights
to the Omacor trademark in Italy, but sells the product under their own trademarks Seacor,
Esapent and Eskim.
|
